DDInter1394 DDInter1435
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Cholecalciferol
Paricalcitol {u} (Compound) resembles {v} (Compound) Calcitriol
Paricalcitol {u} (Compound) resembles {v} (Compound) Calcipotriol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Dihydrotachysterol
Paricalcitol {u} (Compound) binds {v} (Gene) UGT1A4
Paricalcitol {u} (Compound) palliates {v} (Disease) chronic kidney failure
Paricalcitol {u} (Compound) is included by {v} (Pharmacologic Class) Cholecalciferol
Paricalcitol {u} (Compound) causes {v} (Side Effect) Muscle spasms
Paricalcitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Paricalcitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroflumethiazide
Paricalcitol may lead to a major life threatening interaction when taken with Cholecalciferol
Paricalcitol (Compound) resembles Calcitriol (Compound)
Paricalcitol (Compound) resembles Calcipotriol (Compound)
Paricalcitol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Paricalcitol (Compound) binds UGT1A4 (Gene)
Paricalcitol (Compound) palliates chronic kidney failure (Disease)
Paricalcitol (Compound) is included by Cholecalciferol (Pharmacologic Class)
Paricalcitol (Compound) causes Muscle spasms (Side Effect)
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide